2 active not recruiting, 1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Progressive Fibrosing Interstitial Lung Disease: new trials by email Literature Review of Progressive Fibrosing Interstitial Lung Disease trials Research Report on Progressive Fibrosing Interstitial Lung Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease | Phase 2 | Active not recruiting | Endeavor Biomedicines, Inc. | 213 | 2024-11-15 | 2026-02-24 |
| Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease Hyperpolarized xenon-129 MRI - Progressive Fibrosing Interstitial Lung Disease | Active not recruiting | University of Aarhus | 30 | 2023-10-05 | 2025-12-09 | |
| Efficacy & Safety of Nintedanib in Patients With Progressive Fibrosing Coal Mine Dust-Induced Interstitial Lung Disease Nintedanib, Placebo - Progressive Fibrosing Interstitial Lung Disease | Phase 3 | Withdrawn | West Virginia University | 2021-11-01 | 2025-02-24 | |
| Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases ADAMM- RSM Device - Progressive Fibrosing Interstitial Lung Disease, Lung Transplant | Not applicable | Completed | University of Alberta | 8 | 2021-07-01 | 2023-04-19 |
Bronchiectasis (1) · Cystic Fibrosis (1) · Idiopathic Pulmonary Fibrosis (1) · Pulmonary Fibrosis (1) · Tuberculosis, Pulmonary (1)
Lung Diseases (2) · Respiratory Tract Diseases (2) · Actinomycetales Infections (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Bronchial Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Fibrosis (1) · Genetic Diseases, Inborn (1) · Gram-Positive Bacterial Infections (1) · Infant, Newborn, Diseases (1) · Infections (1) · Lung Diseases, Interstitial (1) · Mycobacterium Infections (1)
LY2940680 (1) · nintedanib (1)
Endeavor Biomedicines, Inc. (1) · University of Aarhus (1) · University of Alberta (1) · West Virginia University (1)
Canada (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Denmark (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Malaysia (1) · Mexico (1) · New Zealand (1) · South Korea (1) · United Kingdom (1)
Elisabeth Bendstrup, Professor (1) · Giovanni Ferrara, MD (1) · Lisa Lancaster, M.D. (1) · Rahul Sangani, MD (1)